Danish Pharmacovigilance Update, 27 June 2013

24 July 2013

In this issue of Danish Pharmacovigilance Update:

  • The benefits of medicines for the treatment of acne (Diane® Mite and others) continue to outweigh the risks of use within the indication (front page)
  • The EMA recommends restrictions in the use of retigabine (Trobalt®) (p 2)
  • Thiazides and hyponatraemia – reports to the Capital Region of Denmark's Adverse Drug Reaction Manager at the Department of Clinical Pharmacology at Bispebjerg Hospital (p 3)
  • ADR reports to the Danish Health and Medicines Authority concerning hyponatraemia from the use of thiazides (p 4)
  • Acute pancreatitis and hepatitis associated with the use of vildagliptin (Galvus®) and linagliptin (Trajenta®) reported as potential adverse reactions (p 5)
  • Reports of adverse reactions from the use of Gardasil® during the period 2009-2012 (pp 6-11)
  • New report from the Danish Health and Medicines Authority on the consumption of and adverse reactions from immunomodulatory biological drugs (p 12)

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.